Form 4: Organon & Co. CFO Matthew Walsh Reports Stock Option Grant and RSU Vesting

Chief Financial Officer of Organon & Co., Matthew Walsh, reports the vesting of Restricted Stock Units (RSUs) and the grant of stock options.

Summary

• Matthew Walsh, the CFO of Organon & Co., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On March 31, 2025, Walsh was granted stock options for 317,656 shares of common stock, which will vest in three equal installments starting March 31, 2026.
• He also received 64,640 Restricted Stock Units (RSUs) that vest in three equal installments beginning March 31, 2026.
• Additionally, RSUs granted in previous years vested on March 31, 2025: 15,070 RSUs from March 29, 2024, 12,046 RSUs from March 31, 2023, and 7,754 RSUs from March 31, 2022.
• Walsh disposed of shares to cover tax obligations related to the RSU vesting, with 7,422 shares sold at $14.51 and 5,933 shares sold at $14.51 and 3,819 shares sold at $14.51.
• Following these transactions, Walsh directly owns 133,084 shares of Organon common stock, 317,656 stock options, 64,640 unvested RSUs, 30,142 RSUs, 12,047 RSUs and 0 RSUs.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
• The vesting of RSUs indicates continued employment and contribution to the company.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces Walsh's direct ownership.

Future Outlook

The stock options and RSUs vest over the next three years, incentivizing continued performance.

Industry Context

Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders, a common practice in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in publicly traded companies, particularly in the pharmaceutical sector.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules (three equal installments over three years) are also typical in the industry.

Stakeholder Impact

• Shareholders may view the equity-based compensation as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the executive compensation package as a reflection of the company's commitment to rewarding performance.

Key Dates

Keywords

Organon & Co., Matthew Walsh, CFO, Stock Options, RSU, Restricted Stock Units, Form 4, Beneficial Ownership, Vesting